Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2018
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
2 registry-linked trialsAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 101 papers.
0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Expanded Access Intermediate-Size Patient Population Protocol
Who cites it
101 citing papers in PubMed.
- NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Cancer discovery · 2024Trial
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.JAMA oncology · 2021Trial
- Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Trial
- Trial
- Spectrofluorometric and spectrophotometric assay of anticancer drug ensartinib using ion-pair complex formation reaction with eosin Y.Scientific reports · 2026Article
- Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Development and Validation of a UPLC-MS/MS Method for Simultaneous Quantification of Ensartinib and Its Major Metabolite M465 in Rat Plasma and Application to Pharmacokinetic Studies.Drug design, development and therapy · 2026Article
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- FDA-Approved Fluorine-Containing Molecules in 2024: Significance, Synthesis, and Therapeutic Applications.Current topics in medicinal chemistry · 2026Review
- A model-free phase I/II dose optimization design for immunotherapy trials.Statistical methods in medical research · 2025Article
- Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies.Journal of pharmaceutical analysis · 2025Review
- Ensartinib for advanced or metastatic non-small-cell lung cancer withEClinicalMedicine · 2025Article
- Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage.Translational lung cancer research · 2025Article
- Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion.Frontiers in oncology · 2025Article
- Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors.Frontiers in pharmacology · 2025Article
- Treatment process of ALK and ROS1 double-rearranged lung adenocarcinoma cell carcinoma: a case report.AME case reports · 2025Article
- Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.International journal of general medicine · 2025Review
- [Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment-Literature Review.Biomedicines · 2024Review
- New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Leora HornVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. leora.horn@vanderbilt.edu.
Jeffrey R InfanteTennessee Oncology, PLLC/SCRI, Nashville, Tennessee.
Karen L ReckampCity of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0000-0002-9213-0325
George R BlumenscheinDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ticiana A LealDepartment of Medicine, University of Wisconsin, Madison, Wisconsin.
Saiama N WaqarDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
Barbara J GitlitzDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California.
Rachel E SanbornProvidence Thoracic Oncology Program, Earle A. Chiles Research Institute, Providence Cancer Center, Providence, Oregon.ORCID 0000-0003-0542-6054
Jennifer G WhisenantVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Liping DuDepartment of Biostatistics, Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
Joel W NealDepartment of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California.
Jon P GockermanNovella Clinical, Morrisville, North Carolina.
Gary DukartXcovery Holding Company, Palm Beach Gardens, Florida.
Kimberly HarrowXcovery Holding Company, Palm Beach Gardens, Florida.
Chris LiangXcovery Holding Company, Palm Beach Gardens, Florida.
James J GibbonsXcovery Holding Company, Palm Beach Gardens, Florida.
Allison HolzhausenXcovery Holding Company, Palm Beach Gardens, Florida.
Christine M LovlyVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Heather A WakeleeDepartment of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California.
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MThe Vanderbilt Institute for Clinical and Translational Research (VICTR) KL2KL2RR024977 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$3.0MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)KL2TR000446 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$2.8MNCATS NIH HHS KL2 TR000446NCATS NIH HHS UL1 TR002243NCI NIH HHS K12 CA090625NCRR NIH HHS KL2 RR024977
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAnaplastic Lymphoma KinaseAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalDose-Response Relationship, DrugFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaplan-Meier EstimateLung NeoplasmsAnaplastic Lymphoma KinaseAntineoplastic AgentsensartinibPiperazinesProtein Kinase InhibitorsPyridazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01625234ClinicalTrials.gov
NCT04146571ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.